Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell science at last weekend’s Association of Health Care Journalism 2015 conference.
“There’s an inherent flaw in our system,” said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. “Companies are driven by the desire for profits rather than the desire to find the best therapy, and they often give up on discoveries too early.”
Weissman cited studies that were done long ago at Stanford and proven in mouse models or human clinical trials that pharmaceutical companies have failed to develop. “In mice, transplantation of purified blood stem cell and insulin producing cells from closely related mice leads to a permanent cure,” Weissman says. “We discovered that 16 years ago, and a therapy is still not available.”
A therapy involving high-dose chemotherapy followed by purified stem cell transplant for stage 4 breast cancer cured a relatively high number of women in a small trial almost 20 years ago but the pharmaceutical company with the rights to the technology decided not to develop the treatment, Weissman says. A larger trial of this therapy is currently being planned at Stanford (…)